TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02523378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Edmonton Symptom Assessment Scale
Description: Participants complete the symptom survey alone, or with the help of a research nurse or assistant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Edmonton Symptom Assessment Scale
Description: Participants complete the symptom survey alone, or with the help of a research nurse or assistant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
Study: NCT05612334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise (5 minutes warm-up-30 minutes walking-5 minutes cooling down)
Description: the breathing exercise group, which constituted the placebo control group, were first informed by the researcher about the correct breathing techniques and was given an informative training brochure prepared by the researcher containing the correct breathing exercise information.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: exercise (5 minutes warm-up-30 minutes walking-5 minutes cooling down)
Description: the breathing exercise group, which constituted the placebo control group, were first informed by the researcher about the correct breathing techniques and was given an informative training brochure prepared by the researcher containing the correct breathing exercise information.
Study: NCT01178099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Oral, daily for 12 days
Study: NCT03650699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electropalatography Biofeedback Training
Description: The study agent is electropalatography (EPG). The LinguaGraph EPG device is a biofeedback technology that creates a digital visualization of tongue function during speech. The visualization is accomplished by a custom made mouthpiece that fits over the hard palate with 62 sensors that capture tongue position. The information from the sensors in the mouthpiece, as well as the audio output, is processed in an EPG Unit that converts the information from mouthpiece to a visual representation on a computer screen. The visual information with respect to tongue position can be used to provide biofeedback training.The computer can be used in the clinic during a patient visit or it can be seen over the internet with the patient at home and the speech and language pathologist at the clinic.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electropalatography Biofeedback Training
Description: The study agent is electropalatography (EPG). The LinguaGraph EPG device is a biofeedback technology that creates a digital visualization of tongue function during speech. The visualization is accomplished by a custom made mouthpiece that fits over the hard palate with 62 sensors that capture tongue position. The information from the sensors in the mouthpiece, as well as the audio output, is processed in an EPG Unit that converts the information from mouthpiece to a visual representation on a computer screen. The visual information with respect to tongue position can be used to provide biofeedback training.The computer can be used in the clinic during a patient visit or it can be seen over the internet with the patient at home and the speech and language pathologist at the clinic.
Study: NCT00697632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Description: Oral daily administration without interruption
Study: NCT05652712

Intervention type: DRUG
Intervention: Toripalimab
Description: Toripalimab injection, recommended dose is 3 mg/kg, intravenous infusion every 2 weeks or 240 mg fixed dose, intravenous infusion every 3 weeks.~Other treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
Study: NCT00870987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine prime
Description: 2 mg total dose (1 mg per construct in a volume of 1 mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus type 5 vaccine boost
Description: 2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
Study: NCT03694431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tech-supported HBPC
Description: Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard HBPC
Description: Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
Study: NCT02255084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1 remove self sample kit at gp consulting room or perform pap smear
Description: Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.~Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2 perform self sample at home or pap smear
Description: Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.
Study: NCT03263572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally via spinal tap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally via spinal tap
Study: NCT01012765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol o.d. delivered via SDDPI
Study: NCT03263572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO
Study: NCT03087903

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape Seed Extract
Description: Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
Study: NCT02154256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing incentives
Description: Offer incentives that increase over time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decreasing incentives
Description: offer incentives that decrease over time
Study: NCT00982657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-060 + sunitinib
Description: CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-060 + sunitinib
Description: CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
Study: NCT02154256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stable incentives
Description: offer incentives that are stable over time, but higher than usual care
Study: NCT03190278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART123v1.2
Description: Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab
Study: NCT01857297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enzira® vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enzira® vaccine
Study: NCT03657849

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS TBNA
Description: All patients undergo EBUS TBNA with two needle sizes
Study: NCT03257683

Intervention type: DRUG
Intervention: Ranolazine
Description: Study group will receive additional therapeutic dosing of drug.
Study: NCT00048347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVONEX
Description: 30µg IM every week for 12 weeks
Study: NCT03795220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutinus + transfer day 6
Description: Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutinus + transfer day 7
Description: Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Lutinus + transfer day 6
Description: Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Lutinus + transfer day 7
Description: Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
Study: NCT01521663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX159
Study: NCT00982657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-060 + sunitinib
Description: CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-060 + sunitinib
Description: CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-060 + sunitinib
Description: CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg sunitinib daily (4 out of 6 weeks)
Study: NCT01326845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study: NCT02810925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENS T6
Description: Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENS T6
Description: Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TENS T11/T12
Description: Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric 1200 Kcal/day diet
Description: Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
Study: NCT00383994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein followed by 1000 mg/m\^2 weekly for 3 weeks for a total of 4 doses.
Study: NCT01012765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol o.d. delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol o.d. delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol o.d. delivered via SDDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol o.d. delivered via SDDPI
Study: NCT01813162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir 1% gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal product
Study: NCT02008162

Intervention type: DRUG
Intervention: Bronchodilators
Description: Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
Study: NCT03674866

Intervention type: DRUG
Intervention: Insulin degludec
Description: Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
Study: NCT01521663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04254601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B.
Description: NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet B.
Description: NBUB: DIXWELL EMLY 98 -ABRP 64 ,made in France. Red LLL, InGaAs (630 nm, 10 mW, continuous) (RIKTA, Russia)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical erythromycin cream 2% (Akne-Mycin- Egypt)
Description: two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves
Study: NCT00318032

Intervention type: DRUG
Group type: OTHER
Intervention: multi-factorial intervention
Study: NCT03138265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT Device: ergometer
Description: Supervised exercise training.
Study: NCT01319539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study: NCT04254601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical erythromycin cream 2% (Akne-Mycin- Egypt)
Description: two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical erythromycin cream 2% (Akne-Mycin- Egypt)
Description: two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves
Study: NCT03828851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domiciliary care - Activities of Daily Living
Description: Home-based ADL training.
Study: NCT01918280

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Seminal analyses and testicular biopsy
Description: Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Seminal analyses and testicular biopsy
Description: Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
Study: NCT01478724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk proteins fraction
Description: capsules, one per day, 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk proteins fraction
Description: capsules, one per day, 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk proteins fraction
Description: capsules, one per day, 24 months
Study: NCT04043650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartSteps
Description: HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
Study: NCT02022163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of H7 VLP vaccine + Alhydrogel
Description: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Med dose of H7 VLP vaccine + Alhydrogel
Description: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of H7 VLP vaccine + Alhydrogel
Description: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of H7 VLP vaccine
Description: High dose of H7 VLP vaccine, 2 doses given 21 days apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 doses given 21 days apart
Study: NCT04093440

Intervention type: OTHER
Group type: OTHER
Intervention: lifestyle modification
Description: nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
Study: NCT03213834

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest thoracoscopy
Description: Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest fibrinolytic therapy
Description: A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tPA
Description: tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DNase
Description: DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
Study: NCT03570359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta-1A
Description: Interferon Beta-1A via inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via inhalation
Study: NCT01319539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02190994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: used intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: used intravenously
Study: NCT00892775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)
Description: Vaccine will be administered subcutaneously in the left upper arm (deltoid region)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' 208136, new formulation
Description: Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
Study: NCT02190994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: used intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: used as tablet form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: used as tablet form

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: used as tablet form
Study: NCT01418066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ayurvedic Herbs
Description: A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.